2-219418809-A-T
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM1PM2PM5PP3_StrongPP5
The NM_001927.4(DES):c.347A>T(p.Asn116Ile) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 13/22 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. N116S) has been classified as Likely pathogenic.
Frequency
Consequence
NM_001927.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DES | NM_001927.4 | c.347A>T | p.Asn116Ile | missense_variant | 1/9 | ENST00000373960.4 | NP_001918.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DES | ENST00000373960.4 | c.347A>T | p.Asn116Ile | missense_variant | 1/9 | 1 | NM_001927.4 | ENSP00000363071 | P1 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 exome Cov.: 92
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Desmin-related myofibrillar myopathy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 29, 2022 | This variant is not present in population databases (gnomAD no frequency). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Asn116 amino acid residue in DES. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 20829228, 22403400, 26676851). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt DES protein function. ClinVar contains an entry for this variant (Variation ID: 228547). This variant has not been reported in the literature in individuals affected with DES-related conditions. This sequence change replaces asparagine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 116 of the DES protein (p.Asn116Ile). - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Jul 02, 2015 | The p.Asn116Ile variant in DES has not been previously reported in individuals w ith cardiomyopathy. Of note, a different amino acid alteration at this position (p.Asn116Ser) has been reported de novo in 1 individual with early-onset ARVC an d myofibrillar myopathy (Klauke 2010). Data from large population studies is ins ufficient to assess the frequency of this variant. Computational prediction tool s and conservation analysis suggest that the p.Asn116Ile variant may impact the protein, though this information is not predictive enough to determine pathogeni city. In summary, the clinical significance of the p.Asn116Ile variant is uncert ain. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at